Fellow
Nagoya University Hospital, Japan
1. Koike H, *Nishida Y, Kohno K, Shimoyama Y, Motoi T, Hamada S, Kawai A, Ogose A, Ozaki T, Kunisada T, Matsumoto Y, Matsunobu T, Ae K, Gokita T, Sakai T, Shimizu K, Ishiguro N. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study. Hum Pathol. 2019 Feb; 84:155-163.
Pubmed ID: 30292627
2. Koike H, *Nishida Y, Shinomura T, Zhuo L, Hamada S, Ikuta K, Ito K, Kimata K, Ushida T, Ishiguro N. Forced expression of KIAA1199, a novel hyaluronidase, inhibits tumorigenicity of low-grade chondrosarcoma. J Orthop Res. 2020 Sep;38(9):1942-1951.
Pubmed ID: 32068299
3. Koike H, *Nishida Y, Ito S, Shimoyama Y, Ikuta K, Urakawa H, Sakai T, Shimizu K, Ito K, Imagama S.Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors. World Neurosurg. 2022 Jan;157:e207-e214. doi: 10.1016/j.wneu.2021.09.130. Epub 2021 Oct 6.
Pubmed ID: 34624521
4. Koike H, *Nishida Y, Shinomura T, Ohkawara B, Ohno K, Zhuo L, Kimata K, Ushida T, Imagama S.Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase. Int J Mol Sci. 2022 Apr 7;23(8):4089. doi: 10.3390/ijms23084089.
Pubmed ID: 35456905 Journal Citation Reports Impact Factor: 4.56
5. Koike H, Hamada S, Sakai T, Shimizu K, Yoshida M, *Nishida Y Is tumour location a prognostic factor for pharmacological treatment in patients with desmoid-type fibromatosis? a systematic review. Jpn J Clin Oncol. 2020 Sep 5;50(9):1032-1036. doi: 10.1093/jjco/hyaa078.
Pubmed ID: 32533161
